SFY 2022 - 2023 MC MLR Summary
HIV SNP line of business
| SFY 2022 - 2023 MC MLR Summary | |||||||
|---|---|---|---|---|---|---|---|
| HIV SNP line of business | |||||||
| Plan | MLR AFTER Credibility Adjustment |
Medical Expense (Total Numerator) |
Premium (Total Denominator) |
Remittance | Credible | MMs | |
| Amida Care Inc. | 91.91% | $472,096,501 | $524,794,714 | $0 | Partially Credible | 104,913 | |
| MetroPlus Health Plan, Inc | 100.69% | $255,190,458 | $260,588,702 | $0 | Partially Credible | 55,616 | |
| VNS (d/b/a VNSNY Choice) and Subsidiary | 95.42% | $196,480,376 | $213,470,485 | $0 | Partially Credible | 37,420 | |
| Total | $923,767,335 | $998,853,901 | $0 | 197,949 | |||
NOTES:
Please note that the Remittance is for this line of business for one year ONLY based on a MLR Target of 86%.
No remittance for plan if Non-Credible
